deferasirox has been researched along with Local Neoplasm Recurrence in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bakr, AF; El-Sherbiny, IM; Kabil, MF; Mahmoud, MY; Zaafar, D | 1 |
| Della Porta, M; Fenaux, P; Finelli, C; Gattermann, N; Guerci-Bresler, A; Habr, D; Marcellari, A; Rose, C; Roubert, B; Schmid, M; Stadler, M; Taylor, K; Vassilieff, D | 1 |
1 trial(s) available for deferasirox and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzoates; Blood Platelets; Child; Deferasirox; Female; Follow-Up Studies; Hemoglobins; Humans; Iron Chelating Agents; Iron Overload; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neutrophils; Prognosis; Prospective Studies; Survival Rate; Transfusion Reaction; Triazoles; Young Adult | 2012 |
1 other study(ies) available for deferasirox and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Switching indication of PEGylated lipid nanocapsules-loaded with rolapitant and deferasirox against breast cancer: Enhanced in-vitro and in-vivo cytotoxicity.
Topics: Animals; Breast Neoplasms; Deferasirox; Female; Humans; Lipids; Mice; Nanocapsules; Neoplasm Recurrence, Local; Polyethylene Glycols; Spiro Compounds | 2022 |